Jeffrey Himmelreich - MAIA Biotechnology Head Finance
| MAIA Stock | USD 1.67 0.09 5.11% |
Executive
Jeffrey Himmelreich is Head Finance of MAIA Biotechnology
| Age | 50 |
| Address | 444 West Lake Street, Chicago, IL, United States, 60606 |
| Phone | 312 416 8592 |
| Web | https://maiabiotech.com |
Jeffrey Himmelreich Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Himmelreich against MAIA Biotechnology stock is an integral part of due diligence when investing in MAIA Biotechnology. Jeffrey Himmelreich insider activity provides valuable insight into whether MAIA Biotechnology is net buyers or sellers over its current business cycle. Note, MAIA Biotechnology insiders must abide by specific rules, including filing SEC forms every time they buy or sell MAIA Biotechnology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Himmelreich six days ago Acquisition by Jeffrey Himmelreich of 10000 shares of MAIA Biotechnology at 2.94 subject to Rule 16b-3 | ||
Jeffrey Himmelreich over a month ago Acquisition by Jeffrey Himmelreich of 10000 shares of MAIA Biotechnology at 1.81 subject to Rule 16b-3 |
MAIA Biotechnology Management Efficiency
The company has return on total asset (ROA) of (1.1961) % which means that it has lost $1.1961 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.3102) %, meaning that it created substantial loss on money invested by shareholders. MAIA Biotechnology's management efficiency ratios could be used to measure how well MAIA Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of March 24, 2025, Return On Tangible Assets is expected to decline to -2.4. In addition to that, Return On Capital Employed is expected to decline to -2.81. At present, MAIA Biotechnology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.59, whereas Total Assets are forecasted to decline to about 7.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Karin Heidemann | Champions Oncology | N/A | |
| Subra Sankar | Nautilus Biotechnology | 66 | |
| Harold Waitz | Lineage Cell Therapeutics | 83 | |
| Sean JD | Genelux Common | 56 | |
| Peter Molloy | Portage Biotech | N/A | |
| Pierre Kyme | Armata Pharmaceuticals | N/A | |
| Thomas Dalton | Cingulate | N/A | |
| Ronan JD | Lyra Therapeutics | 52 | |
| MS MD | Armata Pharmaceuticals | 50 | |
| Andrea Park | Portage Biotech | N/A | |
| Arthur Hanson | Champions Oncology | N/A | |
| Steven Innaimo | Portage Biotech | N/A | |
| Justin Fairchild | Portage Biotech | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Doug BA | Dyadic International | N/A | |
| David House | Armata Pharmaceuticals | N/A | |
| Adam Melero | Portage Biotech | N/A | |
| Ana Rodriguez | Dyadic International | N/A | |
| Bryan Kadotani | Armata Pharmaceuticals | N/A | |
| Nick Nelson | Nautilus Biotechnology | 41 | |
Management Performance
| Return On Equity | -11.31 | ||||
| Return On Asset | -1.2 |
MAIA Biotechnology Leadership Team
Elected by the shareholders, the MAIA Biotechnology's board of directors comprises two types of representatives: MAIA Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MAIA. The board's role is to monitor MAIA Biotechnology's management team and ensure that shareholders' interests are well served. MAIA Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MAIA Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, President, CoFounder | ||
| Joseph McGuire, Chief Officer | ||
| Sergei Gryaznov, Chief Officer | ||
| Jeffrey Himmelreich, Head Finance | ||
| Mihail MD, Chief Devel | ||
| Linda Moreira, Company Secretary |
MAIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MAIA Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.31 | ||||
| Return On Asset | -1.2 | ||||
| Current Valuation | 42.21 M | ||||
| Shares Outstanding | 28.92 M | ||||
| Shares Owned By Insiders | 26.40 % | ||||
| Shares Owned By Institutions | 5.29 % | ||||
| Number Of Shares Shorted | 950.6 K | ||||
| Price To Book | 31.45 X | ||||
| EBITDA | (20.18 M) | ||||
| Net Income | (19.77 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.